Hassabis steps back from DeepMind to focus on Isomorphic Labs

Aug 5, 2026 · Issue 1 · 3 sources, 3 articles

Demis Hassabis is stepping down as CEO of Google DeepMind, taking a chief scientist role at Alphabet and focusing on Isomorphic, the drug-discovery startup. Jeff Dean is leaving to start his own venture.

Who is affected and how

pharmaceuticals

One of the flagship AI drug-discovery ventures is getting leadership attention, which could affect partnership talks.

Narrative: AI is rewriting drug development

Sources

• Demis Hassabis says he's 'leaning into' Isomorphic role amid Alphabet and DeepMind shakeupendpoints.news · Aug 5, 2026
• Demis Hassabis steps down from Google DeepMind CEO role amid a major AI leadership shake-up | Fortunefortune.com · Aug 5, 2026
• Google Shakes Up Leadership as Demis Hassabis Steps Back from DeepMind to All-In on AI Drug Discovery with Isomorphic Labs-VCBeatvcbeathealth.com · Aug 6, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.